234 related articles for article (PubMed ID: 36661735)
1. Cost-Effectiveness Analysis of Hp and New Gastric Cancer Screening Scoring System for Screening and Prevention of Gastric Cancer.
Zheng P; Liu J
Curr Oncol; 2023 Jan; 30(1):1132-1145. PubMed ID: 36661735
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.
Qin S; Wang X; Li S; Tan C; Zeng X; Luo X; Yi L; Peng L; Wu M; Peng Y; Wang L; Wan X
Pharmacoeconomics; 2022 Jul; 40(7):725-737. PubMed ID: 35701687
[TBL] [Abstract][Full Text] [Related]
3. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
5. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
Wang Q; Jin PH; Lin GW; Xu SR; Chen J
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
Kowada A
Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES).
Xiang W; Wang R; Bai D; Yu TH; Chen XZ;
Nutr Cancer; 2022; 74(8):2769-2778. PubMed ID: 35876250
[TBL] [Abstract][Full Text] [Related]
9. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review.
Sarmasti M; Khoshbaten M; Khalili F; Yousefi M
J Gastrointest Cancer; 2022 Dec; 53(4):1093-1103. PubMed ID: 34694594
[TBL] [Abstract][Full Text] [Related]
13. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies.
Areia M; Carvalho R; Cadime AT; Rocha Gonçalves F; Dinis-Ribeiro M
Helicobacter; 2013 Oct; 18(5):325-37. PubMed ID: 23566268
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China.
Feng T; Zheng Z; Xu J; Cao P; Gao S; Yu X
Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011621
[TBL] [Abstract][Full Text] [Related]
15. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
[TBL] [Abstract][Full Text] [Related]
17. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan.
Saito S; Azumi M; Muneoka Y; Nishino K; Ishikawa T; Sato Y; Terai S; Akazawa K
Eur J Health Econ; 2018 May; 19(4):545-555. PubMed ID: 28550494
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of eradication of Helicobacter pylori in gastric cancer survivors after endoscopic resection of early gastric cancer.
Shin DW; Yun YH; Choi IJ; Koh E; Park SM
Helicobacter; 2009 Dec; 14(6):536-44. PubMed ID: 19889071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
